Similar articles for PMID: 29194581

Year	Number of Results
2000	1
2003	1
2005	1
2006	3
2007	2
2008	2
2009	1
2010	5
2011	3
2012	5
2013	7
2014	7
2015	11
2016	15
2017	10
2018	12
2019	11
2020	9
2021	8
2022	3
2023	2
2024	0

1

Hodgkin lymphoma: A review and update on recent progress.

Shanbhag S, Ambinder RF. Shanbhag S, et al. CA Cancer J Clin. 2018 Mar;68(2):116-132. doi: 10.3322/caac.21438. Epub 2017 Dec 1. CA Cancer J Clin. 2018. PMID: 29194581 Free PMC article. Review.

2

Managing Risk in Hodgkin Lymphoma.

Armitage JO, Chen RW, Moskowitz CH, Sweetenham J. Armitage JO, et al. Clin Adv Hematol Oncol. 2015 Feb;13(2 Suppl 1):1-19. Clin Adv Hematol Oncol. 2015. PMID: 26430791

3

A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.

Taçyıldız N, Tanyıldız HG, Ünal E, Dinçaslan H, Asarcıklı F, Aksoy BA, Vatansever G, Yavuz G. Taçyıldız N, et al. Turk J Pediatr. 2019;61(5):671-676. doi: 10.24953/turkjped.2019.05.005. Turk J Pediatr. 2019. PMID: 32104998 Free article.

4

Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.

Elshenawy MA, Shahzad Rauf M, Elhassan TAM, Maghfoor I, Akhtar S. Elshenawy MA, et al. Ann Hematol. 2018 Jul;97(7):1229-1240. doi: 10.1007/s00277-018-3283-z. Epub 2018 Feb 26. Ann Hematol. 2018. PMID: 29484455

5

Novel Therapies in the Treatment of Hodgkin Lymphoma.

Andrade-Gonzalez X, Ansell SM. Andrade-Gonzalez X, et al. Curr Treat Options Oncol. 2021 Mar 23;22(5):42. doi: 10.1007/s11864-021-00840-5. Curr Treat Options Oncol. 2021. PMID: 33755826 Review.

6

Standard therapies versus novel therapies in Hodgkin lymphoma.

Gallamini A, Di Raimondo F, La Nasa G, Romano A, Borra A, Greco M. Gallamini A, et al. Immunol Lett. 2013 Sep-Oct;155(1-2):56-9. doi: 10.1016/j.imlet.2013.09.011. Epub 2013 Oct 16. Immunol Lett. 2013. PMID: 24140162 Review.

7

A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.

Milgrom SA, Jauhari S, Plastaras JP, Nieto Y, Dabaja BS, Pinnix CC, Smith GL, Allen PK, Lukens JN, Maity A, Oki Y, Fanale MA, Nasta SD. Milgrom SA, et al. Cancer. 2017 Apr 15;123(8):1363-1371. doi: 10.1002/cncr.30482. Epub 2016 Dec 16. Cancer. 2017. PMID: 27984652 Free PMC article.

8

Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.

Gupta A, Gokarn A, Rajamanickam D, Punatar S, Thippeswamy R, Mathew L, Bagal B, Kannan S, Khattry N. Gupta A, et al. J Cancer Res Ther. 2018 Jul-Sep;14(5):926-933. doi: 10.4103/0973-1482.181183. J Cancer Res Ther. 2018. PMID: 30197327 Free article.

9

How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT.

Mei M, Chen R. Mei M, et al. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):26-33. doi: 10.1016/j.clml.2017.11.003. Epub 2017 Dec 9. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29233742 Review.

10

Treatment for relapse in stage I/II Hodgkin's lymphoma after initial single-modality treatment.

Rueda A, Olmos D, Viciana R, Alba E. Rueda A, et al. Clin Lymphoma Myeloma. 2006 Mar;6(5):389-92. doi: 10.3816/CLM.2006.n.015. Clin Lymphoma Myeloma. 2006. PMID: 16640815

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year